metformin has been researched along with Inflammatory Response Syndrome, Systemic in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-one patients with systemic inflammatory response syndrome and a blood glucose level of >120 mg/dl admitted to an intensive care unit (ICU) were randomised to receive either intravenous infusion of IIT alone (n=11) or combined with metformin (IIT+MET; n=10) to maintain a blood glucose level (BGL) of 80-120 mg/dl." | 5.13 | How does blood glucose control with metformin influence intensive insulin protocols? Evidence for involvement of oxidative stress and inflammatory cytokines. ( Abdollahi, M; Ahmadi, H; Ansari, G; Kajbaf, F; Khajavi, MR; Khalili, H; Mojtahedzadeh, M; Najafi, A; Rouini, MR, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ansari, G | 1 |
| Mojtahedzadeh, M | 1 |
| Kajbaf, F | 1 |
| Najafi, A | 1 |
| Khajavi, MR | 1 |
| Khalili, H | 1 |
| Rouini, MR | 1 |
| Ahmadi, H | 1 |
| Abdollahi, M | 1 |
| Krysiak, R | 1 |
| Gdula-Dymek, A | 1 |
| Okopien, B | 1 |
2 trials available for metformin and Inflammatory Response Syndrome, Systemic
| Article | Year |
|---|---|
How does blood glucose control with metformin influence intensive insulin protocols? Evidence for involvement of oxidative stress and inflammatory cytokines.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Clinical Protocols; Cytokines; Drug Therapy, Combination; Hum | 2008 |
Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia.
Topics: Blood Glucose; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Double-Blind Method; Drug A | 2011 |